GlassScriptPhysician profile
Peter K Ahn
NPI 1568909901
$2,278.02
in general payments reported to CMS, 2019-2025
16 companies · $800 in 2025
The $800 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.48 · 2022: $204 · 2023: $480 · 2024: $757 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,036.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $686.15 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $531.16 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $238.42 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $160.16 | 2023-2025 | |
| Redhill Biopharma INC. | $139.71 | 2022-2024 | Talicia |
| Abbott Laboratories | $122.04 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $116.42 | 2025 | Airsupra |
| Shield Therapeutics INC | $64.82 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.25 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $34.40 | 2025 | Capvaxive, Gardasil 9, Enflonsia |
| Pfizer INC. | $29.64 | 2024 | |
| Sanofi-Aventis U.S. LLC | $26.55 | 2025 | |
| Hologic Sales and Service, LLC | $23.07 | 2024 | Thinprep 2000 Processor, Aptima |
| Glaxosmithkline, LLC. | $16.99 | 2025 | Benlysta |
| Boston Scientific Corporation | $16.86 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $14.38 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.